Louise Emmett
Researcher Next ID · RN-042850
Researcher · Biochemistry, Genetics and Molecular Biology
Sydney, New Zealand
- Works count
- 330
- Citation count
- 14,424
- H-index
- 56
- i10-index
- 161
Research interests
Publications
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00135-9
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00529-6
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
European Urology · 2023 · https://doi.org/10.1016/j.eururo.2023.02.002
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
European Journal of Nuclear Medicine and Molecular Imaging · 2023 · https://doi.org/10.1007/s00259-023-06255-8
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00605-2
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
European Journal of Nuclear Medicine and Molecular Imaging · 2021 · https://doi.org/10.1007/s00259-021-05245-y
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00237-3
TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
British Journal of Urology · 2019 · https://doi.org/10.1111/bju.14876
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Journal of Nuclear Medicine · 2017 · https://doi.org/10.2967/jnumed.117.197160
Prospective Comparison of 18 F-Fluoromethylcholine Versus 68 Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Journal of Nuclear Medicine · 2015 · https://doi.org/10.2967/jnumed.115.160382
Current projects
No projects listed.